A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some ...

Sweden has surpassed the UNAIDS 95-95-95 targets, with reduced HIV incidence and a steady increase in diagnosed and treated ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

At the time of passing, the patient had several medical conditions related to a very high HIV viral load and resistance to ARV,” the DOH said. The patient was admitted to hospital on Sept.

The national HIV prevalence was 16.3% among adults aged 15 years and older, translating to an estimated 7.4 million adults ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

The decrease in CD4 cells during HIV infection seems to be driven by immune activation, which does not always correlate with viral load. Experienced clinicians are all too familiar with the ...

Having an undetectable viral load means there is not enough of the virus in the body to be transmittable, so elite controllers cannot pass the virus on to others. “Someone is generally defined as an ...

Obr and Schur first crossed paths while working on HIV-1 (Human Immunodeficiency Virus ... This shell serves a critical function: it protects the viral genetic material until the host cell is ...

Early on, human immunodeficiency virus (HIV) causes flu-like symptoms, which are similar across sexes. HIV symptoms in women may differ after the initial infection and include changes in menstrual ...

New data to be shared on GSK’s RSV vaccine across different age groups of patients at increased risk • Efficacy data for gepotidacin in ...